Enterococcal infections & antimicrobial resistance

Indian Journal of Medical Research

Volumn 128, Issue 2, 2008, Pages 111-121

  Sood, Seema ^a   Malhotra, Meenakshi ^a   Das, B K ^a   Kapil, Arti ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Enterococcus faecalis; Enterococcus faecium; High level aminoglycoside resistance (HLAR); Nosocomial infections; Vancomycin resistant enterococci (VRE)

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AVOPARCIN; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLINDAMYCIN; ERYTHROMYCIN; GENTAMICIN; KANAMYCIN; LATAMOXEF; METICILLIN; METRONIDAZOLE; NETILMICIN; NOVOBIOCIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; PIPERACILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TEICOPLANIN; TETRACYCLINE DERIVATIVE; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

AMINO TERMINAL SEQUENCE; ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM CONTAMINATION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BLOOD CULTURE; CARBOXY TERMINAL SEQUENCE; COMMUNICABLE DISEASE; DIARRHEA; DISEASE SEVERITY; DRUG TREATMENT FAILURE; ENTEROCOCCAL INFECTION; ENVIRONMENTAL FACTOR; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; MEDICATION ERROR; MICROBIAL GROWTH; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; NONHUMAN; PENICILLIN ALLERGY; PHENOTYPE; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SPECIES DIFFERENCE; URINARY TRACT INFECTION;

CROSS INFECTION; DEMOGRAPHY; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INDIA; RISK FACTORS; VANCOMYCIN RESISTANCE; VIRULENCE;

EID: 55849096934     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Murray BE. The life and times of the enterococcus. Clin Microhiol Rev 1990; 3: 45-65.
2. Lancefield RC. A serological differentiation of human and other groups of haemolytic streptococci. J Exp Med 1933; 57: 571-95.
3. Sherman JM. The streptococci. Bacteriol Rev 1937; 1: 3-97.
4. Schleifer KH, Kilpper-Balz R. Transfer of Streptococcus faecalis and Streptococcus faecium to the genus Enterococcus nom. rev. as Enterococcus faecalis comb. nov. and Enterococcus faecium comb. nov. Int J Syst Bacteriol 1984; 34: 31-4.
5. Edwards DD. Enterococci attract attention of concerned microbiologists. ASM News 2000; 66: 540-5.
6. Moellering RC Jr. Enterococcus species, Streptococcus bovis, and Leuconostoc species. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Oouglas and Bennett's principles and practice of infectious diseases. 5th ed. Vol. 2. New York: Churchill Livingstone; 2000. p. 2147-56.
7. Bhat KG, Paul C, Ananthakrishna NC. Drug resistant enterococci in a south Indian hospital. Trop Doct 1998; 28: 106-7.
8. Facklam RR, Teixeira LM. Enterococcus. In: Lollier L, Balows A, Sussman M, editors. Topley & Wilson's microbiology and microbial infections. 9th ed. New York: Oxford University Press; 1998. p. 669-82.
9. Low DE, Keller N, Barth A, Jones RN. Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial 'surveillance Program. 1997-1999 Clin Infect Dis 2001: 32 (Supply 2): S133-45.
10. Schaberg DR, Culver DH, Gaynes RR Major trends in the microbial etiology of nosocomial infection. Am J Med 1991 91: 72S-75S.
11. Murray BE. Diversity among multidrug-resistant enterococci. Emerg Infect Dis 1998; 4: 37-47.
12. Mundy LM, Sahm DF, Gilmore M. Relationships between enterococcal virulence and antimicrobial resistance. Clin Microbiol Rev 2000; 13: 513-22.
13. Hospital Infections Program. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999; 27: 520-32.
14. Ratanasuwan W, Iwen PC, Hinrichs SH, Rupp ME. Bacteremia due to motile Enterococcus species: clinical features and outcomes. Clin Infect Dis 1999; 28: 1175-7.
15. Mohanty S, Jose S, Singhal R, Sood S, Dhawan B, Das BK, et al. Species prevalence and antimicrobial susceptibility of enterococci isolated in a tertiary care hospital of north India. Southeast Asian J Trop Med Public Health 2005; 36: 962-5.
16. Kapoor L, Randhawa VS, Deb M. Antimicrobial resistance of enterococcal blood isolates at a pediatric care hospital in India. Jpn J Infect Dis 2005; 58: 101-3.
17. Taneja N, Rani P, Emmanuel R, Sharma M. Significance of vancomycin resistant enterococci from urinary specimens at a tertiary care centre in northern India. Indian J Med Res 2004; 119: 72-4.
18. Uttley AH, Collins CH, Naidoo J, George R. Vancomycin-resistant enterococci. Lancet 1988; i: 57-8.
19. Woodford N. Johnson AP, Morrison D, Speller DC. Current perspectives on glycopeptide resistance. Clin Microbiol Rev 1995; 8: 585-615.
20. Centers for Disease Control and Prevention (COC). Nosocomial enterococci resistant to vancomycin in United States, 1989-1993. MMWR Morb Mortal Wkly Rep 1993; 42: 597-9.
21. McDonald LC, Kuehnert MJ, Tenover FC, Jarvis WR. Vancomycin-resistant enterococci outside the health-care setting: prevalence, sources, and public health implications. Emerg Infect Dis 1997; 3: 311-7.
22. Bates J. Epidemiology of vancomycin-resistant enterococci in the community and the relevance of farm animals to human infection. Hosp Infect 1997; 37: 99-101.
23. Centinkaya Y, Falk P, Mayliall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev 2000; 13: 686-707.
24. Bonten MJ, Slaughter S,AmbergenAW, HaydenMK, van Voorhis J, Nathan C, et al. The role of "colonization pressure" in the spread of vancomycin-resistant enterococci. an important infection control variable. Arch Intern Med 1998; 158: 1127-32.
25. Boyce JM. Vancomycin -resistant enterococcus. Detection, epidemiology and control measures. Infect Dis Clin North Am 1997; 11: 367-84.
26. Wade JJ. The emergence of Enterococcus faecium resistant to glycopeptides and other standard agents - a preliminary report. J Hosp Infect 1995; 30 (Suppl): 483-93.
27. Beezhold DW, Slaughter S, Hayden MK, Matushek M, Nathan C, Trenholme GM, et al. Skin colonization with vancomycin -resistant enterococci among hospitalized patients with bacteremia. Clin Infect Dis 1997; 24: 704-6.
28. Boyce JM, Opal SM, Chow JW, Zervos MJ, Potter-Bynoe G, Sherman CB, et al. Outbreak of multi-drug resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol 1994; 32: 1148-53.
29. Boyce JM, Mermel LA, Zervos MJ, Rice LB, Potter-Bynoe G, Giorgio C, et al. Controlling vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 1995; 16: 634-7.
30. Karanfil LV, Murphy M, Josephson A, Gaynes R, Mandel L, Hill BC, et al. A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit. Infect Control Hosp Epidemiol 1992; 13: 195-200.
31. Frieden TR, Munsiff SS, Low DE, Willey BM, Williams G, Faur Y, et al. Emergence of vancomycin- resistant enterococci in New York City. Lancet 1993; 342: 76-9.
32. Hunt CP. The emergence of enterococci as a cause of nosocomial infection. Br J Biomed Sci 1998; 55: 149-56.
33. Isenberg HD, editor. Clinical microbiology procedure handbook, vol.1. Tests to detect high-level aminoglycoside resistance in enterococci. Washington DC: American Society of Microbiology; 1992. p. 5.4.1-5.4.8.
34. Suppola JP, Kolho E, Salmenlinna S, Tarkka E, Vuopio-Varkila J, Vaara M. vanA and vanB incorporate into an endemic ampicillin-resistant vancomycin-sensitive Enterococcus faecium strain: effect on interpretation of clonality. J Clin Microbiol 1999; 37: 3934-9.
35. Loeb M, Salama S, Armstrong-Evans M, Capretta G, Olde J. A case-control study to detect modifiable risk factors for colonization with vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 1999; 20: 760-3.
36. Arthur M, Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother 1993; 37: 1563-71.
37. Fines M, Perichon B, Reynolds P, Sahm DF, Courvalin P. VanE, a new type of acquired glycopeptide resistance in Enterococcus faecalis BM4405. Antimicrob Agents Chemother 1999; 43: 2161-4.
38. Perichon B, Reynolds P, Courvalin P. VanD-type glycopeptide-resistant Enterococcus faecium BM4339. Antimicrob Agents Chemother 1997; 41: 2016-8.
39. Quintiliani R Jr, Courvalin P. Conjugal transfer of the vancomycin resistance determinant vanB between enterococci involves the movement of large genetic elements from chromosome to chromosome. FEMS Microbiol Lett 1994; 119: 359-63.
40. Quintiliani R Jr, Evers S, Courvalin P. The vanB gene confers various levels of self-transferable resistance to vancomycin in enterococci. J Infect Dis 1993; 167: 1220-3.
41. Dutka-Malen S, Blaimont B, Wauters G, Courvalin P. Emergence of high-level resistance to glycopeptides in Enterococcus gallinarum and Enterococcus casseliflavus. Antimicrob Agents Chemother 1994; 38: 1675-7.
42. Hayden MK, Trenholme GM, Schultz JE, Sahm DF. In vivo development of teicoplanin resistance in a VanB Enterococcus faecium isolate. J Infect Dis 1993; 167: 1224-7.
43. Eliopoulos GM. Vancomycin-resistant enterococci. Mechanism and clinical relevance. Infect Dis Clin North Am 1997; 11: 851-65.
44. Wu Z, Wright GD, Walsh CT. Overexpression, purification, and characterization of VanX, a D-,D-dipeptidase which is essential for vancomycin resistance in Enterococcus faecium BM4147. Biochemistry 1995; 34: 2455-63.
45. Arthur M, Molinas C, Depardieu F, Courvalin P. Characterization of Tn I546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J Bacteriol 1993; 175: 117-27.
46. Bugg TD, Wright GD, Dutka-Malen S, Arthur M, Courvalin P, Walsh CT. Molecular basis of vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. Biochemistry 1991; 30: 10408-15.
47. Bugg TD, Dutka-Malen S, Arthur M, Courvalin P, Walsh CT. Identification of vancomycin resistance protein VanA as a D-alanine: D-alanine ligase of altered substrate specificity. Biochemistry 1991; 30: 2017-21.
48. Arthur M, Molinas C, Dutka-Malen S, Courvalin P. Structural relationship between the vancomycin resistance protein VanH and 2-hydroxycarboxylic acid dehydrogenases. Gene 1991; 103: 133-4.
49. Baptista M, Depardieu F, Courvalin P, Arthur M. Specificity of induction of glycopeptide resistance genes in Enterococcus faecalis. Antimicrob Agents Chemother 1996; 40: 2291-5.
50. Evers S, Sahm DF, Courvalin P. The vanB gene of vancomycin-resistant Enterococcus faecalis V583 is structurally related to genes encoding D-Ala: D-Ala ligases and glycopeptide-resistance proteins VanA and VanC. Gene 1993; 124: 143-4.
51. Clewell DB. Movable genetic elements and antibiotic resistance in enterococci. Eur J Clin Microbiol Infect Dis 1990; 9: 90-102.
52. B two-component regulatory system in Enterococcus faecalis V583. J Bacteriol 1996; 178: 1302-9.
53. Clark NC, Cooksey RC, Hill BC, Swenson JM, Tenover FC. Characterization of glycopeptide-resistant enterococci from U.S. hospitals. Antimicrob Agents Chemother 1993; 37: 2311-7.
54. Courvalin P. Resistance of enterococci to glycopeptides. Antimicrob Agents Chemother 1990; 34: 2291-6.
55. Dever LL, Smith SM, Handwerger S, Eng RH. Vancomycin-dependent Enterococcus faecium isolated from stool following oral vancomycin therapy. J Clin Microbiol 1995; 33: 2770-3.
56. Mathur P, Kapil A, Chandra R, Sharma P, Das B. Antimicrobial resistance in Enterococcus faecalis at a tertiary care centre of northern India. Indian J Med Res 2003; 118: 25-8.
57. Karmarkar MG, Gershom ES, Mehta PR. Enterococcal infections with special reference to phenotypic characterization & drug resistance. Indian J Med Res 2004; 119 (Suppl): 22-5.
58. Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP. Vancomycin -resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996; 23: 1234-9.
59. Morris JG Jr, Shay DK, Hebden JN, McCarter RJ Jr, Perdue BE, Jarvis W, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a University mediated centre. Ann Intern Med 1995; 123: 250-9.
60. Shankar V, Baghdayan AS, Huycke MM, Lindahl G, Gilmore MS. Infection-derived Enterococcus faecalis strains are enriched in esp, a gene encoding a novel surface protein. Infect Immun 1999; 67: 193-200.
61. Garbutt JM, Littenberg B, Evanoff BA, Sahm D, Mundy LM. Enteric carriage of vancomycin-resistant Enterococcus faecium in patients tested for Clostridium difficile. Infect Control Hosp Epidemiol 1999; 20: 664-70.
62. Livornese LL Jr, Dias S, Samel C, Romanowski B, Taylor S, May P, et al. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann Intern Med 1992; 117: 112-6.
63. Tornieporth NG, Roberts RB, John J, Hafner A, Riley LW. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1996; 23: 767-72.
64. Centers for Disease Control and Prevention. Recommendations for preventing spread of vancomycin resistance. Hospital Infection Control Practices Advisory Committee (HICPAC). Infect Control Hosp Epidemiol 1995; 16: 105-13.
65. Herman DJ, Gerding DN. Screening and treatment of infections caused by resistant enterococci. Antimicrob Agents Chemother 1991; 35: 215-9.
66. Murray BE. Vancomycin-resistant enterococci. Am J Med 1997; 102: 284-93.
67. Caron F, Pestel M, Kitzis MD, Lemeland JF, Humbert G, Gutmann L. Comparison of different beta-lactam-glycopeptide-gentamicin combinations for an experimental endocarditis caused by a highly beta-lactam-resistant and highly glycopeptide-resistant isolate of Enterococcus faecium. J Infect Dis 1995; 171: 106-12.
68. Bartoloni A, Colao MG, Orsi A, Dei R, Giganti E, Parenti F. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile. J Antimicrob Chemother 1990; 26: 627-33.
69. Schwalbe RS, McIntosh AC, Qaiyumi S, Johnson JA, Johnson RJ, Furness KM, et al. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob Agents Chemother 1996; 40: 2416-9.
70. Eliopoulos GM, Wennersten CB, Gold HS, Moellering RC Jr. In vitro activities in new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother 1996; 40: 1745-7.